Quantum Biopharma Ltd.
QNTM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for QNTM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · QNTM
Quantum Biopharma Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and inflammatory conditions, with its lead candidate Lucid-MS targeting multiple sclerosis and a pipeline including FSD201 for mast cell activation syndrome.
Key risk: No product sales
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 12 clinical trials for Quantum Biopharma Ltd..
Quantum Biopharma Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and inflammatory conditions, with its lead candidate Lucid-MS targeting multiple sclerosis and a pipeline including FSD201 for mast cell activation syndrome.
- Lead candidate Lucid-MS is advancing toward a Phase 2 efficacy trial in multiple sclerosis, with an oral formulation being manufactured by a CDMO [sec · filed 2026-03-26].
- The company reported cash & equivalents of $1.9M and shareholders' equity of $30.5M as of December 31, 2025 [sec].
- FSD201 (ultramicronized palmitoylethanolamide) is in a Phase 2 trial for mast cell activation syndrome, with first participants expected in Q2 2026 [sec · filed 2026-03-26].
- The company has no product sales and a limited operating history, making it difficult to evaluate its business and assess future prospects [sec · filed 2026-03-26].
What works
- Lucid-MS has shown in numerous animal models over the past decade that it helped animals regain their ability to walk, supporting its potential as a treatment for mobility loss in MS [sec · filed 2026-03-26].
- The company has sufficient working capital as of December 31, 2025 to carry out planned operations over the next twelve months [sec · filed 2026-03-26].
- The company intends to retain 100% of the rights to develop products for pharmaceutical use, which could maximize future value if successful [sec · filed 2026-03-26].
What to weigh
- Drug development is highly uncertain, and the company has no product sales, with a limited operating history that makes it difficult to evaluate its business [sec · filed 2026-03-26].
- The company faces significant competition from established therapies for progressive multiple sclerosis, including ocrelizumab and siponimod, from larger companies with greater resources [sec · filed 2026-03-26].
- The company's cryptocurrency treasury activities divert management attention and resources from its core biopharmaceutical programs, potentially slowing progress [sec · filed 2026-03-26].
- The company cannot reasonably estimate the actual amounts necessary to successfully complete development and regulatory approval for Lucid-MS or other product candidates [sec · filed 2026-03-26].
From the filings
Quoted directly from source documents.
Lucid-MS has demonstrated efficacy in animal models for regaining mobility.
“To date numerous animal models over the past decade showed Lucid-MS helped those animals regain their ability to walk.”
SEC filings · March 26, 2026
The company has sufficient working capital for the next twelve months.
“Management has concluded that the Company has sufficient working capital as of December 31, 2025 to carry out its planned operations over the next twelve months.”
SEC filings · March 26, 2026
The company faces competition from established MS therapies.
“There are a few approved therapies for progressive multiple sclerosis, including ocrelizumab by Roche and siponimod by Novartis, both of which are immunomodulatory drugs.”
SEC filings · March 26, 2026
Cryptocurrency activities divert resources from core business.
“The diversion of management focus and operational resources to cryptocurrency treasury management could slow the progress of our biopharmaceutical programs and adversely affect”
SEC filings · March 26, 2026
Risks & what to watch (4)›
Key risks
- No product sales — The company has no product sales and a limited operating history, making it difficult to evaluate its business and assess future prospects [sec · filed 2026-03-26].
- Uncertain development costs — The company cannot reasonably estimate the actual amounts necessary to successfully complete development and regulatory approval for any product candidates [sec · filed 2026-03-26].
- Competition from larger firms — Competitors may have significantly greater financial, technical, and human resources, and may obtain regulatory approval before the company [sec · filed 2026-03-26].
- Cryptocurrency distraction — Cryptocurrency treasury activities divert management attention and resources from core biopharmaceutical programs [sec · filed 2026-03-26].
What to watch
- Initiation of the Phase 2 efficacy trial for Lucid-MS in multiple sclerosis, with drug substance manufacturing ongoing through Q3 2026 [sec · filed 2026-03-26].
- First participants in the Phase 2 trial of FSD201 for mast cell activation syndrome, expected in Q2 2026 [sec · filed 2026-03-26].
- Completion of drug product manufacturing for Lucid-MS Phase 2 studies, expected by Q4 2026 [sec · filed 2026-03-26].
- Any updates on the company's working capital position and cash runway beyond the next twelve months [sec · filed 2026-03-26].
Sources: SEC filings · Generated August 27, 2026 · How we verify sources →
Run Quantum Biopharma Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Quantum Biopharma Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
32.2 months
D/E 1.19
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
20
Total value held
$865K
| Holder | Shares | Value |
|---|---|---|
| advisorshares investments llc | 108,591 | $524K |
| jane street group, llc | 31,501 | $152K |
| citadel advisors llc | 15,863 | $77K |
| marex group plc | 13,468 | $65K |
| osaic holdings, inc. | 6,375 | $31K |
| atlantic union bankshares corp | 1,000 | $5K |
| farther finance advisors, llc | 1,000 | $4K |
| jones financial companies lllp | 700 | $3K |
| cetera trust company, n.a | 250 | $1K |
| wells fargo & company/mn | 100 | $477 |
Showing top 10 of 20 institutional holders of Quantum Biopharma Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 5.4%
- Days to cover
- 0.5
- Shares short
- 282,526
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
QNTM short interestFrequently asked questions
What is the AI investment thesis for Quantum Biopharma Ltd.?
Quantum Biopharma Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and inflammatory conditions, with its lead candidate Lucid-MS targeting multiple sclerosis and a pipeline including FSD201 for mast cell activation syndrome.
Who is the CEO of Quantum Biopharma Ltd.?
Mr. Zeeshan Saeed is the chief executive officer of Quantum Biopharma Ltd. (QNTM).
Where is Quantum Biopharma Ltd. headquartered?
Quantum Biopharma Ltd. (QNTM) is headquartered in Toronto, ON, Canada.
What therapeutic areas does Quantum Biopharma Ltd. focus on?
Quantum Biopharma Ltd. develops therapies across Oncology, Pain, Dermatology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.